Etudes cliniques en cours
Découvrez ici la liste des différentes études cliniques en cours classées par centre.
CHU Liège
- PDC –LUNG-101 : An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer (NSCLC)
- REALEC : A multicenter non-interventional cohort study to evaluate the realworld clinical management and outcomes of patients diagnosed with ALK-positive advanced NSCLC treated with ALECTINIB (REALEC)
- MARIPOSA-2 : A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure)
- CARMEN EFC158-58 : Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic nonsquamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors
- CA001-050: A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
- ETOP 13-18 BEAT-meso : A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma
- Amgen 20190288 (ouverture mars 2022) : A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-Line Treatment (CodeBreaK 201)
- AEGAN : A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)
- LUMINOSITY : A Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
CHU Mont-Godinne
Etudes sponsorisées interventionnelles en cours:
- PEARLS: A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy.
- Intr@pid: A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Nonsmall Cell Lung Cancer.
Etudes sponsorisées non interventionnelles en cours:
- BEPACT Lung: Impact of Patient Characteristics on pneumo-oncologists NSCLC systemic treatment decision in Belgium: A cross-sectional study.
Etudes académiques non interventionnelles en cours:
- ELCWP: Cardiovascular morbidities and lung cancer treatment: a prospective registry.
Cliniques Universitaires Saint-Luc
Etudes Onco en cours | |||
|
1st line
| |||
|
Acronyme
|
Studies
|
Cancer
|
PI
|
|
BO29554 study (B-FAST)
|
A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial)
|
NSCLC (ROS+) A venir: BRAF V600+
|
P.C
|
|
ADRIATIC (D933QC00001)
|
Phase III, randomised, double-blind, placebo-controlled, multi-centre study assessing the efficacy and safety of durvalumab or durvalumab and tremelimumab in patients with LD-SCLC who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy (CRT)
|
SCLC limités post-chimioradio
|
T.P
|
|
ANAM 17-21
|
A phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to evaluate the efficacy and safety of Anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced NSCLC
|
NSCLC cachexia
|
T.P
|
|
Zenith20 (Spectrum) (SPI-POZ-202)
|
Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)
|
NSCLC IV EGFR ou HER2 exon 20 inser/mut
|
T.P
|
|
CA209-73L
|
A Phase 3, Randomized, Open-Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab Plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA NSCLC)
|
NSCLC IIIA/B/C
|
TP
|
|
2nd line
| |||
|
ImmunoSABR
|
Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer
|
NSCLC IV
|
X.G
|
|
AMG510 (20190009)
|
A Phase 3 Multicenter, Randomized, Open
Label, Active-controlled, Study of AMG 510
Versus Docetaxel for the Treatment of Previously
Treated Locally Advanced and Unresectable or
Metastatic NSCLC Subjects With Mutated KRAS
p.G12C
|
NSCLC KRAS p.G12C
|
ThP
|
|
≥ 3rd line
| |||
|
ImmunoSABR
|
Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer
|
NSCLC IV
|
X.G
|
|
Autres
| |||
|
Acronyme
|
Studies
|
Cancer
|
PI
|
|
EORTC: E2-Radiate 1811
|
E²-RADIatE:
EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe
|
Tous cancers oligométa traités par Rth
|
XG
|
|
PACIFIC R D4194R00005
|
First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
|
NSCLC stage III with durvalumab post chimioradio
|
T.P
|
|
Immuno Poumon
|
Etude prospective des facteurs pronostics et prédictifs de l'immunothérapie dans le cancer du poumon
|
NSCLC
|
FAb
|
|
SPECTA
|
Screening Cancer Patients for Efficient Clinical Trial Access
|
NSCLC IV naïfs/ thymomes, mésothéliome IV naïfs
|
T.P
|
Grand Hôpital de Charleroi (GHdC)
Faites défiler le tableau de gauche à droite pour découvrir l'entièreté des colonnes.
| Pathologies | Etudes-Nom | Etudes-Code | Eudract | NCT | IP | Titre | Type de Sponsor | Phase | Statut | PI | Numero Interne EtudeGHDC |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Poumons et Thorax
|
849-012 (Krystal program)
|
MRT 849-012
|
NCT04685135
|
MRTX849 (KRAS G12C inhibitor)
|
A randomized Phase 3 study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
|
Firme
|
Phase 3
|
Ouverte à l'inclusion
|
Canon Jean-Luc
|
2020-ONCOHEMA-0094
| |
|
Poumons et Thorax
|
PACIFIC-4
|
D9103C00001
|
2018-002572-41
|
NCT03833154
|
Durvalumab
|
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
|
Firme
|
Phase 3
|
Ouverte à l'inclusion
|
Colinet Benoît
|
2019-ONCOHEMA-0111
|
|
Poumons et Thorax
|
PDC-Lung-101
|
PDC-Lung-101
|
2018-002382-19
|
NCT03970746
|
PDC*lung01
|
An open-label, dose escalation phase I/II study assessing the safety and immunogenicity of PDC*lung, therapeutic cancer vaccine, as single agent or in combination with a checkpoint inhibitor, in patients with Non-Small Cell Lung Cancer (NSCLC)
|
Firme
|
Phase 1a
|
Ouverte à l'inclusion
|
Colinet Benoît
|
2018-ONCOHEMA-0159
|
|
Poumons et Thorax
|
MK7339-013
|
MK7339-013
|
2019-003616-31
|
NCT04624204
|
Pembrolizumab (MK-3475)
|
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)
|
Firme
|
Phase 3
|
Ouverte à l'inclusion
|
Colinet Benoît
|
2019-ONCOHEMA-0202
|
|
Poumons et Thorax
|
Skyscraper 03
|
GO41854
|
2019-0044773-29
|
NCT04513925
|
Tiragolumab
|
A phase 3, open-label, randomized study of Atezolizumab and Tiragolumab compared with Durvalumab in patients with locally advanced, unresectable stage 3 non-small cell lung cancer who have not progressed after concurrent platinum-based chemoradiation.
|
Firme
|
Phase 3
|
Ouverte à l'inclusion
|
Colinet Benoît
|
2020-ONCOHEMA-0014
|
|
Poumons et Thorax
|
CA001-050
|
CA001-050
|
NCT04702880
|
BMS-986012
|
A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
|
Firme
|
Phase 2
|
Ouverte à l'inclusion
|
Colinet Benoît
|
2020-ONCOHEMA-0256
| |
|
Poumons et Thorax
|
Mariposa-2
|
61186372NSC3002
|
2021-001825-33
|
NCT04988295
|
Amivantamab
|
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure
|
Firme
|
Phase 3
|
Ouverte à l'inclusion
|
Colinet Benoît
|
2021-ONCOHEMA-0042
|
|
Poumons et Thorax
|
Tropion-Lung08
|
SH 7024395 / DS1062-A-U304 / Keynote-C73
|
2021-002555-10
|
NCT05215340
|
Datopotomab deruxtecan (Dato-DXd) (bispécifique anti TROP-2)
|
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-Small Cell Lung Cancer without Actionable Genomic Alterations (Tropion-LUNG08)
|
Firme
|
Phase 3
|
Ouverture prochaine
|
Colinet Benoît
|
2021-ONCOHEMA-0082
|
|
Toutes Tumeurs
|
GO40311
|
GO40311
|
2019-004596-39
|
NCT03448042
|
BTRC4017A (humanized, full lenght IgG1 anti HER2 / cluster if differentiation 3 (CD3) T cell-dependent bispecific antibody)
|
A PHASE Ia/b, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF BTRC4017A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT AND IN COMBINATION WITH TRASTUZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCER
|
Firme
|
Phase 1
|
Ouverte à l'inclusion
|
Canon Jean-Luc
|
2020-ONCOHEMA-0098
|
|
Toutes Tumeurs
|
Precision 2 – Olaparib
|
1-2018 BSMO
|
2018-002966-37
|
NCT03967938
|
Olaparib (inhibiteurs de PARP)
|
Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes. SAUF SEIN, OVAIRE, PROSTATE, ATM gene
|
Académique
|
Phase 2
|
Ouverte à l'inclusion
|
Canon Jean-Luc
|
2019-ONCOHEMA-0093
|
|
Toutes Tumeurs
|
Precision 1
|
BSMO 2014-2
|
NCT03873103
|
The Belgian Molecular Profiling Program of Metastatic Cancer for Clinical Decision and Treatment Assignment
“PRECISION 1”
|
Académique
|
Prospective-Collection d'échantillons
|
Ouverte à l'inclusion
|
Canon Jean-Luc
|
2020-ONCOHEMA-0022
| ||
|
Toutes Tumeurs
|
TAPISTRY
|
BO41932
|
2020-001847-16
|
NCT04589845
|
Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in patients with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are TMB-high as identified by an next-generation-sequencing (NGS) assay
|
Firme
|
Phase 2
|
Ouverte à l'inclusion
|
Canon Jean-Luc
|
2020-ONCOHEMA-0028
| |
|
Toutes Tumeurs
|
DF1001-001
|
DF1001-001
|
2019-004706-10
|
NCT04143711
|
DF1001 (first-in-class HER2-targeted immunotherapy)
|
A phase I/II, first-in-human, multi-part, open-label, multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics, biological, and clinical activity of DF1001 in patients with locally advanced or metastatic solid tumors, and expansion in selected indications
|
Firme
|
Phase 2
|
Ouverte à l'inclusion
|
Canon Jean-Luc
|
2020-ONCOHEMA-0013
|
|
Toutes Tumeurs
|
BALLETT
|
BSMO2020-2
|
NCT05058937
|
A study to examine the clinical value of comprehensive genomic profiling performed by Belgian NGS laboratories: a Belgian Precision study of the BSMO in collaboration with the Cancer Centre - Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT)
|
Académique
|
Prospective-Collection d'échantillons
|
Ouverte à l'inclusion
|
Canon Jean-Luc
|
2020-ONCOHEMA-0128
| ||
|
Toutes Tumeurs
|
SGNTUC-019
|
SGNTUC-019
|
NCT04579380
|
Tucatinib (tyrosine kinase réversible, ciblant l'HER2)
|
A phase 2 basket study of Tucatinib in combination with Trastuzumab in subjects with previously treated, locally advanced unresectable or metastatic solid tumors driven by HER2 alterations
|
Firme
|
Phase 2
|
Ouverte à l'inclusion
|
Canon Jean-Luc
|
2020-ONCOHEMA-0238
| |
|
Toutes Tumeurs
|
B9991046
|
B9991046
|
2021-002457-29
|
NCT05059522
|
Avelumab
|
Avelumab master protocol: An open-label continuation study for participants continuing from Pfizer-sponsored avelumab clinical studies.
|
Firme
|
Phase 3
|
Ouverte à l'inclusion
|
Canon Jean-Luc
|
2021-ONCOHEMA-0121
|
|
Toutes Tumeurs
|
FORTITUDE-301
|
20210104
|
NCT05325866
|
Bemarituzumab (AMG552) (anti-FGFR2b antibody)
|
A phase 1b/2, multicenter, open-label basket study evaluating the safety and efficacy of bemarituzumab monotherapy in solid tumors with FGFR2b overexpression (FORTITUDE-301)
|
Firme
|
Phase 1b
Phase 2
|
Ouverte à l'inclusion
|
Schroder David
|
2022-ONCOHEMA-0010
| |
|
Toutes Tumeurs
|
Tropics-3
|
IMMU-132-11
|
NCT03964727
|
IMMU-132 (Sacituzumab govitecan)
|
A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors
|
Firme
|
Phase 2
|
Ouverte à l'inclusion
|
Schroder David
|
2019-ONCOHEMA-0030
| |
|
Toutes Tumeurs
|
TAK-981-1002
|
TAK-981-1002
|
2020-003947-27
|
NCT03648372
|
TAK-981 (inhibitor of the SUMOylation enzymatic cascade with potential immune-activating and antineoplastic activities)
|
An open label, dose-escalation, phase 1/2 study to revaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics of TAK-981 in adult patients with advanced or metastatic solid tumors or relapsed/refractory hematologic malignancies and in a subset with coronavirus disease 2019
|
Firme
|
Phase 1
Phase 2
|
Ouverte à l'inclusion
|
Schroder David
|
2020-ONCOHEMA-0245
|